Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.An independent data safety monitoring board has recommended that Via Pharmaceuticals should continue with clinical trials for its cardiovascular drug.
Subscribe to our email newsletter
The data safety monitoring board (DSMB) observed a continued acceptable safety profile, and evidence of a consistent pharmacological effect of its Phase II drug, VIA-2291.
Dr Adeoye Olukotun, chief medical officer, said: “VIA intends to continue the current Phase II trials, and to initiate additional clinical studies. VIA is very encouraged that the safety profile of VIA-2291 indicates that it is well tolerated in patients, and that evidence of a positive pharmacological effect has been observed by the DSMB. We believe that a drug that addresses vascular inflammation in the treatment of atherosclerosis will address a significant unmet medical need.”
VIA expects the top line results from the two Phase II trials for acute coronary syndrome and carotid endarterectomy patients in the middle of 2008.